Trial Profile
Phase I Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs SXL 01 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms PROSTIRNA
- 15 Jan 2021 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.
- 15 Jan 2021 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2020.
- 15 Jan 2021 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.